#United States #San Diego #Phanes Therapeutics #Spevatamig #PACbody

Phanes Therapeutics Announces U.S. Patent for PACbody® Technology

Phanes Therapeutics, Inc., a promising player in the field of immuno-oncology, recently announced the receipt of a significant U.S. patent for its proprietary bispecific antibody platform, PACbody® (Patent No. US12,735,481). This platform is pivotal for the firm’s innovative approach to drug discovery and development, particularly focusing on treatments for cancer.

Founded with the mission to revolutionize cancer therapy, Phanes has established itself as a clinical-stage biotech company committed to creating and advancing drugs that tackle severe unmet medical needs. The granting of the PACbody® patent is a testament to its foundational technology and an essential milestone in strengthening its intellectual property portfolio on a global scale.

Understanding PACbody® Technology

PACbody® stands out as a unique platform that facilitates the development of bispecific antibodies while retaining the essential characteristics of native Immunoglobulin G (IgG). This feature proves beneficial for attaining drug-like properties, essential for successful pharmaceutical formulations. The technology enables the cost-effective production of bispecific antibodies that are not only stable but also highly compatible with existing monoclonal antibody manufacturing processes, thereby lowering the risks associated with clinical and manufacturing activities.

According to Dr. Ming Wang, the Founder and CEO of Phanes Therapeutics, the approval of the PACbody® patent validates their innovative research and development capabilities. He emphasized the platform's role in addressing the challenges that have historically complicated the development of bispecific antibodies, expressing enthusiasm about utilizing it to deliver safer and more effective treatments to cancer patients globally.

Pioneering Advances in Cancer Treatment

One of the flagship products developed from the PACbody® platform is spevatamig (PT886), which has garnered significant attention for its therapeutic potential. Currently in Phase II clinical trials, spevatamig targets claudin 18.2 and CD47. This innovative bispecific antibody has attained several regulatory designations, such as Orphan Drug Designation from the FDA for the treatment of pancreatic cancer and Fast Track designations aimed at expediting its development against metastatic claudin 18.2-positive pancreatic adenocarcinoma, and later for advanced biliary tract carcinoma.

In an exciting collaborative effort, Phanes partnered with Merck (known as MSD in many regions outside the U.S. and Canada) to explore the efficacy of spevatamig in conjunction with pembrolizumab, a prominent immunotherapy drug. The combination of these agents represents a new frontier in immuno-oncology, presenting an opportunity for enhanced treatment responses against solid tumors.

Future Prospects

The excitement surrounding the PACbody® technology and its applications is palpable, with the potential to significantly alter the therapeutic landscape for cancer treatments. Phanes is not stopping at spevatamig—its commitment to developing innovative bispecific antibodies extends to other projects in their pipeline, further leveraging their proprietary platforms: SPECpair® and ATACCbody®, as they tackle unmet challenges in oncology.

As Phanes Therapeutics continues to navigate the complex dynamics of cancer drug development, the company remains at the forefront of redefining treatment paradigms, with a clear focus on delivering breakthrough therapies. The recent patent grant for PACbody® is just one of many steps toward achieving this ambitious mission, potentially transforming the lives of those facing cancer.

For further details and inquiries, interested parties can visit Phanes Therapeutics’ website.